Paolo Bidoli

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta et al. · The Lancet · 2014 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +16

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu et al. · Journal of Clinical Oncology · 2013 · 635 citations

Medicine, Oncology, Pharmacotherapy +16

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu et al. · The Lancet Oncology · 2012 · 614 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8